TGFB1 and neoplasm: Their comprehensive evaluation associated with response and resistance to checkpoint blockade in patients who were treated with an anti-PD-L1 agent (atezolizumab) indicated that TGF-β signaling, which reflected a distinct gene expression signature and involved pSMAD2/3, may counteract anti-tumor immunity by restricting the T-cells in the TME.